Letter concerning "Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival": Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.

Journal Article Corrected proof Letter concerning “Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival”: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma Get access Vincenzo Di Nunno, Vincenzo Di Nunno Department of Oncology, Azienda Unità Sanitaria Locale (AUSL) Bologna, 40139 Bologna, Italy https://orcid.org/0000-0003-4441-9834 Search for other works by this author on: Oxford Academic PubMed Google Scholar Lidia Gatto, Lidia Gatto Department of Oncology, Azienda Unità Sanitaria Locale (AUSL) Bologna, 40139 Bologna, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Alicia Tosoni, Alicia Tosoni Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Stefania Bartolini, Stefania Bartolini Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Enrico Franceschi Enrico Franceschi Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy Corresponding Author: Enrico Franceschi, MD, Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy (e.franceschi@isnb.it). https://orcid.org/0000-0001-9332-4677 Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, noad071, https://doi.org/10.1093/neuonc/noad071 Published: 12 May 2023 Article history Corrected and typeset: 12 May 2023 Published: 12 May 2023